Ascidian Therapeutics launches with $50M to rewrite RNA

From by Jim Cornall

Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, has been launched. 

With an initial focus on replacing mutated exons at the RNA level, Ascidian’s technology enables therapeutic targeting of large genes and genes with high mutational variance while maintaining native gene expression patterns and levels. This approach is designed to provide the durability of gene therapy while reducing risks associated with DNA editing and manipulation…

Ascidian harnesses the RNA splicing machinery of the cell and combines it with large-scale DNA and RNA synthesis, deep sequencing technologies, and clinically validated therapeutic delivery systems, to restore normal protein function and transform the treatment of human disease.


Leave a Reply

Your email address will not be published. Required fields are marked *


Time limit is exhausted. Please reload CAPTCHA.